These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10332533)

  • 81. Ototoxicity associated with dideoxycytidine.
    Powderly WG; Klebert MK; Clifford DB
    Lancet; 1990 May; 335(8697):1106. PubMed ID: 1970411
    [No Abstract]   [Full Text] [Related]  

  • 82. Vancomycin Ototoxicity in patient with normal renal function.
    Traber PG; Levine DP
    Ann Intern Med; 1981 Oct; 95(4):458-60. PubMed ID: 7283300
    [No Abstract]   [Full Text] [Related]  

  • 83. Ototoxicity of erythromycin gluceptate.
    Beckner RR; Gantz N; Hughes JP; Farricy JP
    Am J Obstet Gynecol; 1981 Mar; 139(6):738-9. PubMed ID: 7211980
    [No Abstract]   [Full Text] [Related]  

  • 84. Drug-Induced Ototoxicity: Diagnosis and Monitoring.
    Campbell KCM; Le Prell CG
    Drug Saf; 2018 May; 41(5):451-464. PubMed ID: 29404977
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Screening in larval zebrafish reveals tissue-specific distribution of fifteen fluorescent compounds.
    Yao Y; Sun S; Fei F; Wang J; Wang Y; Zhang R; Wu J; Liu L; Liu X; Cui Z; Li Q; Yu M; Dang Y; Wang X
    Dis Model Mech; 2017 Sep; 10(9):1155-1164. PubMed ID: 28754836
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Screening for chemicals that affect hair cell death and survival in the zebrafish lateral line.
    Ou H; Simon JA; Rubel EW; Raible DW
    Hear Res; 2012 Jun; 288(1-2):58-66. PubMed ID: 22310494
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Hair cell toxicity in anti-cancer drugs: evaluating an anti-cancer drug library for independent and synergistic toxic effects on hair cells using the zebrafish lateral line.
    Hirose Y; Simon JA; Ou HC
    J Assoc Res Otolaryngol; 2011 Dec; 12(6):719-28. PubMed ID: 21732171
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Bilateral sensorineural hearing loss after adjuvant treatment with cyclophosphamide, methotrexate, Fluorouracil and alternative oral medications in a male with breast cancer.
    Marioni G; Lodo M; Cartei G; Zangaglia AM; Staffieri A
    Clin Drug Investig; 2005; 25(4):277-80. PubMed ID: 17523779
    [No Abstract]   [Full Text] [Related]  

  • 89. Cochlear implantation for treatment-induced ototoxic deafness in Langerhans cell histiocytosis. A case report.
    Torkos A; Czigner J; Kiss JG; Tóth F; Szamosközi A; Jóri J
    Eur Arch Otorhinolaryngol; 2005 Jun; 262(6):496-500. PubMed ID: 15942803
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
    Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy.
    Suzuki T; Takeuchi M; Saeki H; Yamazaki S; Koga H; Abe D; Nishimura M; Nakaseko C; Nakasa H; Nakamura H; Ariyoshi N; Kitada M
    Clin Ther; 2010 Mar; 32(3):527-31. PubMed ID: 20399989
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
    Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
    J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
    J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Ototoxicity associated with vinblastine.
    Moss PE; Hickman S; Harrison BR
    Ann Pharmacother; 1999 Apr; 33(4):423-5. PubMed ID: 10332533
    [TBL] [Abstract][Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.